Macrogenics (MGNX)

$1.44 -0.05 (-3.36%)
Market Cap 94.18M
Revenue (ttm) 149.96M
Net Income (ttm) -66.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -44.66%
Debt to Equity Ratio 0.00
Volume 305,300
Avg Vol 1,441,584
Day's Range N/A - N/A
Shares Out 63.21M
Stochastic %K 25%
Beta 1.65
Analysts Sell
Price Target $3.40

Company Profile

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which ha...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 251 5172
Fax: 301 251 5321
Address:
9704 Medical Center Drive, Rockville, United States
topstockalerts
topstockalerts Aug. 21 at 11:31 PM
After Hours Top Gainers PT2 $XPON $MRVI $GWAV $MGNX $TGL
0 · Reply
SkyLonger
SkyLonger Aug. 21 at 9:12 PM
$MGNX market value of outstanding shares is almost 100M....Fly robin fly up up up to shy🤙
0 · Reply
PSDL75
PSDL75 Aug. 21 at 8:48 PM
$MGNX Looks like an insider purchased $150K of shares on the open market https://archive.fast-edgar.com/20250821/ATBCO22CL222M2Z2222A22ZZRNCNZ2Q24272/
0 · Reply
dbr_island
dbr_island Aug. 21 at 8:36 PM
$MGNX there it goes DVLT shouldn’t be under $1 imo 🎯✅ Here’s why👇🚨🚨🚨
0 · Reply
PSDL75
PSDL75 Aug. 19 at 8:16 PM
$MGNX looks like dump to the downside
0 · Reply
PSDL75
PSDL75 Aug. 18 at 5:33 PM
$MGNX Need to shake the $1.60's then we might move. Too easy for them to dink it down on little volume
0 · Reply
PSDL75
PSDL75 Aug. 18 at 10:38 AM
$MGNX aimless with a tight range.... can we pop out to the upside here?
0 · Reply
Budman10
Budman10 Aug. 17 at 1:18 AM
$MGNX I have a feeling we may see a bump soon like we did back in January 2024. Lot of potential pending good news
2 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 2:54 PM
Leerink Partners has adjusted their stance on Macrogenics ( $MGNX ), setting the rating to Outperform with a target price of 8 → 5.
1 · Reply
PSDL75
PSDL75 Aug. 15 at 10:49 AM
$MGNX certainly we can start to move up from here?
1 · Reply
Latest News on MGNX
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

Aug 14, 2025, 4:01 PM EDT - 7 days ago

MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

Aug 13, 2025, 4:01 PM EDT - 8 days ago

MacroGenics Appoints Eric Risser as President and Chief Executive Officer

MacroGenics: Working On That Road To Recovery

Jun 11, 2025, 6:32 PM EDT - 2 months ago

MacroGenics: Working On That Road To Recovery

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

Jun 10, 2025, 7:00 AM EDT - 2 months ago

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 3, 2025, 4:30 PM EDT - 2 months ago

MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 13, 2025, 4:01 PM EDT - 3 months ago

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

MacroGenics Announces Date of First Quarter 2025 Financial Results

May 6, 2025, 4:30 PM EDT - 3 months ago

MacroGenics Announces Date of First Quarter 2025 Financial Results

MacroGenics to Participate in Upcoming Investor Conference

May 1, 2025, 4:30 PM EDT - 4 months ago

MacroGenics to Participate in Upcoming Investor Conference

MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:09 PM EDT - 5 months ago

MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

Mar 6, 2025, 7:30 AM EST - 6 months ago

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

MacroGenics: Stacking Up A Lot Of Headwinds

Feb 27, 2025, 2:08 PM EST - 6 months ago

MacroGenics: Stacking Up A Lot Of Headwinds

MacroGenics to Participate in Upcoming Investor Conferences

Feb 27, 2025, 7:30 AM EST - 6 months ago

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript

Nov 5, 2024, 7:01 PM EST - 10 months ago

MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

Nov 5, 2024, 4:01 PM EST - 10 months ago

MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results

MacroGenics Announces Leadership Transition

Oct 30, 2024, 7:30 AM EDT - 10 months ago

MacroGenics Announces Leadership Transition

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

Oct 29, 2024, 4:30 PM EDT - 10 months ago

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders

Oct 25, 2024, 5:15 PM EDT - 10 months ago

Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

Oct 22, 2024, 7:30 AM EDT - 10 months ago

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX

Sep 24, 2024, 12:57 PM EDT - 11 months ago

Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX

MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm

Sep 24, 2024, 10:30 AM EDT - 11 months ago

MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

Sep 23, 2024, 11:00 AM EDT - 11 months ago

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman

Sep 22, 2024, 11:09 AM EDT - 11 months ago

MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Reach Out To The Schall Law Firm

Sep 21, 2024, 11:00 AM EDT - 11 months ago

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Reach Out To The Schall Law Firm

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders Are Urged To Contact The Schall Law Firm

Sep 19, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc Is Being Sued For Violating Securities Laws And Shareholders Are Urged To Contact The Schall Law Firm

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics

Sep 19, 2024, 9:57 AM EDT - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNX

Sep 19, 2024, 5:45 AM EDT - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNX

MGNX Deadline: Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Sep 17, 2024, 11:23 AM EDT - 1 year ago

MGNX Deadline: Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Hospice Dynamix Welcomes Industry Veteran Rob Stoltz as Chief Strategy Officer

Sep 17, 2024, 11:04 AM EDT - 1 year ago

Hospice Dynamix Welcomes Industry Veteran Rob Stoltz as Chief Strategy Officer

MacroGenics Inc May Have Violated Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm About A Suit

Sep 17, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc May Have Violated Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm About A Suit

Investor Reminder (MGNX):  Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc.  Investors of September 24, 2024 Deadline

Sep 16, 2024, 12:14 PM EDT - 1 year ago

Investor Reminder (MGNX):  Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc.  Investors of September 24, 2024 Deadline

MacroGenics Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Sep 15, 2024, 11:00 AM EDT - 1 year ago

MacroGenics Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

Sep 15, 2024, 3:00 AM EDT - 1 year ago

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

topstockalerts
topstockalerts Aug. 21 at 11:31 PM
After Hours Top Gainers PT2 $XPON $MRVI $GWAV $MGNX $TGL
0 · Reply
SkyLonger
SkyLonger Aug. 21 at 9:12 PM
$MGNX market value of outstanding shares is almost 100M....Fly robin fly up up up to shy🤙
0 · Reply
PSDL75
PSDL75 Aug. 21 at 8:48 PM
$MGNX Looks like an insider purchased $150K of shares on the open market https://archive.fast-edgar.com/20250821/ATBCO22CL222M2Z2222A22ZZRNCNZ2Q24272/
0 · Reply
dbr_island
dbr_island Aug. 21 at 8:36 PM
$MGNX there it goes DVLT shouldn’t be under $1 imo 🎯✅ Here’s why👇🚨🚨🚨
0 · Reply
PSDL75
PSDL75 Aug. 19 at 8:16 PM
$MGNX looks like dump to the downside
0 · Reply
PSDL75
PSDL75 Aug. 18 at 5:33 PM
$MGNX Need to shake the $1.60's then we might move. Too easy for them to dink it down on little volume
0 · Reply
PSDL75
PSDL75 Aug. 18 at 10:38 AM
$MGNX aimless with a tight range.... can we pop out to the upside here?
0 · Reply
Budman10
Budman10 Aug. 17 at 1:18 AM
$MGNX I have a feeling we may see a bump soon like we did back in January 2024. Lot of potential pending good news
2 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 2:54 PM
Leerink Partners has adjusted their stance on Macrogenics ( $MGNX ), setting the rating to Outperform with a target price of 8 → 5.
1 · Reply
PSDL75
PSDL75 Aug. 15 at 10:49 AM
$MGNX certainly we can start to move up from here?
1 · Reply
Estimize
Estimize Aug. 14 at 10:06 PM
$MGNX reported -0.57 EPS and 22.24 revenue for Q2. http://www.estimize.com/intro/mgnx?chart=historical&metric_name=eps&utm_content=MGNX&utm
0 · Reply
Budman10
Budman10 Aug. 14 at 9:46 PM
$MGNX solid report cash burn isn’t what some below express Do your own DD
1 · Reply
Budman10
Budman10 Aug. 14 at 9:45 PM
$MGNX
0 · Reply
DonCorleone77
DonCorleone77 Aug. 14 at 9:27 PM
$MGNX MacroGenics reports Q2 EPS (57c), consensus (38c) -- Q2 revenue $22.24M, consensus $28.06M.
0 · Reply
MarketWarfare
MarketWarfare Aug. 14 at 8:56 PM
$MGNX cash burn is brutal here. They had 201M cash at the end of 2024 and 176M six months later, but that included the 70M from Sagard. So they essentially burned 100M in 6 months. Also foregoing the next 140M in zynyz royalty in the process. Need positive lorigerlimab data, more milestone/royalty payments, and Gilead option exercise. Good number of potential catalysts but the company operates in a shady and secretive manner. Hopefully the new CEO is ready to work and is motivated to actually improve the share price.
2 · Reply
PSDL75
PSDL75 Aug. 14 at 8:15 PM
$MGNX Result Drivers * REVENUE INCREASE - Higher manufacturing volume and increased collaboration revenue drove Q2 revenue to $22.2 mln * ROYALTY AGREEMENT - $70 mln upfront payment from Sagard for ZYNYZ royalty purchase agreement contributed to financial position * COST MANAGEMENT - Decreased R&D and SG&A expenses helped narrow net loss to $36.3 mln
0 · Reply
SkyLonger
SkyLonger Aug. 14 at 8:05 PM
$MGNX well that ER was not on the 19th ? Just released...plenty of CASH it looks like!
0 · Reply
MarketWarfare
MarketWarfare Aug. 14 at 5:31 PM
$MGNX will they just release earnings after the bell and call it a day?
1 · Reply
PSDL75
PSDL75 Aug. 14 at 3:16 PM
$MGNX welp, rug pull CEO change...
0 · Reply
PSDL75
PSDL75 Aug. 13 at 8:11 PM
$MGNX alright sports fans that hate the CEO - he's out MacroGenics Appoints Eric Risser as President and Chief Executive Officer
0 · Reply
MarketWarfare
MarketWarfare Aug. 13 at 8:08 PM
$MGNX So the new CEO is finally announced. I would prefer someone that wasn't already associated with this shitshow of a company. How did it take this long to make this change? This was the result of a grand search for a new leader? Will his first act as CEO be submitting a late filing for earnings? Clown show.
1 · Reply
Estimize
Estimize Aug. 13 at 8:00 PM
Wall St is expecting -0.44 EPS for $MGNX Q3 [Reporting 11/11 AMC] http://www.estimize.com/intro/mgnx?chart=historical&metric_name=eps&utm_c
0 · Reply